key: cord-0816864-95p8et28 authors: Santoro, Francesco; Monitillo, Francesco; Raimondo, Pasquale; Lopizzo, Agostino; Brindicci, Gaetano; Gilio, Michele; Musaico, Francesco; Mazzola, Michele; Vestito, Domenico; Di Benedetto, Rossella; Abumayyaleh, Mohammad; El-Battrawy, Ibrahim; Santoro, Carmen Rita; Di Martino, Luigi Flavio Massimiliano; Akin, Ibrahim; De Stefano, Giulio; Fiorilli, Rosario; Cannone, Michele; Saracino, Annalisa; Angarano, Salvatore; Carbonara, Sergio; Grasso, Salvatore; Di Biase, Luigi; Brunetti, Natale Daniele title: QTc interval prolongation and life-threatening arrhythmias during hospitalization in patients with COVID-19. Results from a multi-center prospective registry date: 2020-10-24 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa1578 sha: a293e6613ac2ef5fb7431b7b593e131508a2fd82 doc_id: 816864 cord_uid: 95p8et28 BACKGROUND: Prolonged QTc interval and life-threatening arrhythmias (LTA) are potential drug induced complications previously reported with antimalarial, antivirals and antibiotics. OBJECTIVES: To evaluate prevalence and predictors of QTc interval prolongation and incidence of LTA during hospitalization for COVID-19 among patients with normal admission QTc. METHODS: 110 consecutive patients were enrolled in a multicenter international registry. 12-lead ECG was performed at admission, after 7 and 14 days; QTc values were analyzed. RESULTS: Fifteen (14%) patients developed a prolonged-QTc (pQT) after 7 days (mean QTc increase 66±20msec, +16%, p<0.001); these patients were older, had higher basal heart rates, higher rates of paroxysmal atrial fibrillation, lower platelet count. QTc increase was inversely proportional to baseline QTc levels and leukocyte count and directly to basal heart rates(p<0.01).At multivariate stepwise analysis including age, male gender, paroxysmal atrial fibrillation, basal QTc values, basal heart rate and dual antiviral therapy, age(OR 1.06, 95% C.I. 1.00-1.13, p<0.05), basal heart rate(OR 1.07, 95% C.I. 1.02-1.13, p<0.01) and dual antiviral therapy(OR 12.46, 95% C.I. 2.09-74.20, p<0.1) were independent predictors of QT-prolongation.Incidence of LTA during hospitalization was 3.6%. One patient experienced cardiac arrest and three non-sustained ventricular tachycardia. LTAs were recorded after a median of 9 days from hospitalization and were associated with 50% of mortality rate. CONCLUSIONS: After 7 days of hospitalization, 14% of patients with Covid-19 developed pQTc; age, basal heart rate and dual antiviral therapy were found as independent predictor of pQTc. Life threatening arrhythmias have an incidence of 3.6% and were associated with poor outcome. Coronavirus disease is an infectious disease caused by a newly discovered coronavirus, presenting mainly as a severe acute respiratory syndrome Aim of the study was therefore to evaluate potential predictors of QTc-interval prolongation and incidence of life threating arrhythmias in COVID-19 patients admitted with normal QTc-interval that started therapy during hospitalization. A c c e p t e d M a n u s c r i p t 5 All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. A c c e p t e d M a n u s c r i p t Continuous variables were reported as means ± standard deviation or median with interquartile range (IQR) and compared with Student's t-test for either paired or unpaired groups and the Mann-Whitney (for unpaired data) and the Wilcoxon rank test (for paired data) as required, dichotomic variables as percentage and compared with  2 test of Fisher test as required. Repeated measures were analyzed with analysis of variance test (ANOVA). Multiple regression analysis was used to identify predictors for prolonged QTc after 7 days and for correcting bias of principal confounders; odds ratio and 95% confidence intervals (CI) were also calculated. A p value <0.05 was considered as statistically significant. One hundred and ten consecutive patients were enrolled in the study. All baseline features are reported in A c c e p t e d M a n u s c r i p t 7 Mean QTc interval after 7 days was 429±30 msec and after 14 days 435±26 msec (Figure 1 ). Fifteen (14%) patients developed a prolonged QTc interval after 7 days (mean QTc at admission 414±16 vs 481±21 msec after 7 days, mean QTc interval increase 66±20 msec, +16%, p<0.001, Figure 2 ). These patients were older (66±12 vs 56±14 years, p<0.05), had higher basal heart rates (87±26 vs 71±11 bpm, p<0.001), higher rates of paroxysmal atrial fibrillation (20% vs 2%, p<0.01), lower platelet count (169±41 vs 231±112 *1000/mm 3 , p<0.05) ( Table 3) . The increase in QTc values was inversely proportional to baseline QTc levels and leucocyte count, both in absolute and in relative terms (r -0.52, r -0.57, p<0.001; r -0.20, r -0.19, p<0.05, respectively), directly to basal heart rates (r 0.33, r 0.28, p<0.01, Figure 3 ). One patient experienced cardiac arrest due to asystole and was resuscitated with advanced circulatory support and three patients had non sustained ventricular tachycardia managed with intravenous beta-blocker (metoprolol) ( Table 4) . Patients experienced life threatening arrhythmias after a median of 9 days (6-21 days) from hospitalization. Life threatening arrhythmias were associated with poor outcome, two out of four patients died 24±12 hours after the index event. A c c e p t e d M a n u s c r i p t 8 Interestingly, one patient showed transient "Brugada type I" ECG pattern during fever that disappeared after paracetamol infusion; the patient was continuously ECG monitored, did not experience arrythmia during hospitalization. He had no history of syncope and was treated during hospitalization with hydroxychloroquine and azithromycin. In the overall population 93% of patients received therapy with hydroxychloroquine, 95% antibiotic therapy (71% macrolide (azithromycin), 30% cephalosporin, 10% betalattamics), 77% antivirals (40% lopinavir/ritonavir, 27% darunarvir/cobicistat, 13% oseltamivir, 6% tenofovir). Among patients receiving dual antiviral therapy (13%), 66% received lopinavir/ritonavir and oseltamivir, 18% lopinavir/ritonavir and darunarvir cobicistat and 16% oseltamivir and darunarvir cobicistat. We report one of the first multi-center registry on COVID-19 patients aiming to evaluate electrocardiographic changes during hospitalization and life-threatening arrhythmias. We found that: 1) After 7 days of hospitalization 14 % of patients developed prolongation of QTc interval, dual antiviral therapy, age and basal heart rate were an independent predictor of pQT. 2) Life threatening arrhythmias have an incidence of 3.6% and may present after a median of 9 days of hospitalization with cardiac arrest and non-sustained VT. 3) Life threatening arrhythmias were featured by poor outcome with 50% of mortality. QTc prolongation is quite common among patients treated with antimalarial, antivirals and antibiotics. Therefore, aim of the study was to evaluate changes of QT interval during hospitalization and potential correlation with life threatening arrythmias among patients with COVID-19 and normal admission QTc interval. Although no adequately sized randomized trials have been published on treatment of COVID-19, a combination of hydroxychloroquine and azithromycin is commonly used to treat this infection. Moreover, some centers started also a combination of antiviral drugs such as lopinavir/ritonavir or remdesevir. These In the present study we found that a combination of antivirals may predict prolonged QTc interval, however due to the heterogenous antivirals combination, no conclusion can be provided. Fifteen patients received two antiviral drugs, among these 10 patients were treated with Lopinavir/ritonavir (200/50 mg daily) and Oseltamivir (75 mg daily). Ritonavir and Oseltamivir are both associated with QT prolongation in previous studies xxii xxiii , therefore their combination could increase risk this risk. In the present study also age and basal heart rate were found to be predictor associated with pQT. These findings may reflect patient's comorbidities and higher fragility of this subset of patients. Indeed, there was a trend not statistically significant of higher rate of intensive care stay for patients that developed prolonged QT interval after 7 days (13 vs 4%). Life threatening arrhythmias in patients with viral infection have been previously described in the context of myocardial inflammation. Several mechanisms are involved in this process: increased oxidative stress and In the present study most of the arrhythmias were cardiac arrest and non-sustained ventricular tachycardia. Arrhythmias occurred mainly during the second week of hospitalization and two patients died after 24±12 h from the index event due to multiorgan failure. Management was conservative and betablockers were administered. As shown also in previous studies 24 , no patients experienced ventricular fibrillation following torsade de pointes. Moreover, three out of four patients that experienced lifer threatening arrhythmias were in intensive care unit; therefore, arrhythmias seem to be related more with a severe progression of the disease. During intensive care unit stay, sedatives -hypnotics, benzodiazepines or alpha-2 adrenergic agonist were also administered to obtain light sedation, that was useful to tolerate mechanical ventilation. However, especially the use of dexmedetomidine, an alpha-2 adrenergic agonist, was associated with bradycardia that could increase the risk of QTc prolongation xxvi . This study shows that young patients without significant comorbidities may be candidate for domiciliary treatment with a relative low risk of arrhythmic complication. However, baseline ECG with exclusion of inherited long QT syndrome and conduction disturbances (as bundle branch block) should be warranted to all patients before treatment. Some limitations have to be considered for the present investigation. The study evaluated a relatively low number of patients. Continuous ECG monitoring was performed only in case of intensive care unit hospitalization. The population enrolled consisted of symptomatic patients that required hospitalization. A c c e p t e d M a n u s c r i p t 11 During hospitalization, 7 days after admission, 14% of patients developed QTc prolongation; Dual antiviral therapy, age and basal heart rate were the only independent predictors of QT prolongation at 7 days. Life threatening arrhythmias have an incidence of 3.6% and were associated with poor outcome. None to disclose. A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study Compassionate Use of Remdesivir for Patients with Severe Covid-19 Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection Pharmacologic Treatments for Coronavirus Disease Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! Circulation ix Lombardy Section Italian Society Infectious And Tropical Diseases -. Vademecum for the treatment of people with COVID-19 Comparison of QT Interval Measurement Methods and Correction Formulas in Atrial Fibrillation Which QT Correction Formulae to Use for QT Monitoring Urgent Guidance for Navigating and Circumventing the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID-19 Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters Blockade of HERG channels by HIV protease inhibitors Azithromycin-induced torsade de pointes Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments Conduction abnormalities and ventricular arrhythmogenesis: the roles of sodium channels and gap junctions Electrophysiological alterations in a murine model of chronic coxsackievirus B3 myocarditis